Intersect ENT (XENT) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Leerink Partners Cuts Price Target on Intersect ENT (XENT) to $14; Reiterates Outperform
November 3, 2016 7:41 AM EDTLeerink Partners maintained an Outperform rating on Intersect ENT (NASDAQ: XENT), and cut the price target to $14.00 (from $21.00), following the company's 3Q and sell-off. Revenues of $18.5M beat consensus $17.8M and reflected a second consecutive quarter of y/y sales growth acceleration.
Analyst Richard Newitter commented, "Following XENT's massive... More
